Hier steht ein Titel. Dieser Titel kann auch drei Zeilen haben.

1
Ihre Fördermöglichkeiten im 7. EU-Rahmenprogramm
(7.RP) für Forschung und Entwicklung Ylva
Huber Bereich Europäische und Internationale
Programme FFG Österreichische
Forschungsförderungsgesellschaft
2
Inhalt

• Generelle Gesichtspunkte des 7.
  EU-Rahmenprogramms
• Health und Food, Agriculture and Fisheries, and
  Biotechnology in der 1. Ausschreibung
• Das Programm IDEAS

3
Inhalt

• Generelle Gesichtspunkte des 7.
  EU-Rahmenprogramms
• Health und Food, Agriculture and Fisheries,
  and Biotechnology in der 1. Ausschreibung
• Das Programm IDEAS

4
(No Transcript)
5
Budget FP7 für Common Approach

• Cooperation 32.315
• Health 6.000
• Biotech, Food, Agriculture 1.935
• Information Society 9.120
• Nanomaterials Production 3.505
• Energy 2.300
• Environment 1.900
• Transport 4.195
• Socio-economic Research 610
• Security and Space 2.750
• Ideas 7.460
• People 4.728
• Capacities 4.267

Total 50.521 billion EUR (incl. Joint Research
Centre 1,7 Mrd)
6
Instrumente im 7. RP
7. EU-Rahmenprogramm 6. EU-Rahmenprogramm
Verbundprojekte (Collaborative Projects) Integrierte Projekte (IP) Gezielte Forschungsprojekte (STREPs)
Exzellenznetze (NoE) Exzellenznetze (NoE)
Koordinierungsmaßnahmen (CA) Koordinierungsmaßnahmen (CA)
Unterstützungsmaßnahmen (SSA) Unterstützungsmaßnahmen (SSA)
Unterstützung für Ausbildung und Karriereentwicklung (Marie-Curie) Unterstützung für Ausbildung und Karriereentwicklung (Marie-Curie)
Einzelprojekte im ERC (Programm Ideas)
KMU spezifische Maßnahmen KMU spezifische Maßnahmen
Artikel 169 Artikel 169
ERA-NET und ERA-NET PLUS ERA-NET
Gemeinsame Technologieinitiativen (JTI)
7
Förderhöhen im 7. RP

• Abschaffung der Kostenmodelle
• Forschung und Entwicklung Förderung bis zu 75
• Universitäten
• Forschungsorganisationen
• Öffentliche Einrichtungen
• KMU
• Unternehmen 50
• Demonstration bis zu 50
• Grundlagenforschung bis zu 100
• Specific Support Actions und Coordination
  Actions bis zu 100
• Pauschalen für indirekte Kosten sind möglich
• Vereinfachung der Abläufe

8
Technologieplattformen und Gemeinsame
Technologieinitiativen

• Mobilisierung europäischer Ressourcen im Bereich
  Forschung, technologische Entwicklung und
  Innovation durch Zusammenbringen aller Akteure
  eines definierten Forschungsbereiches (Industrie,
  KMU, Universitäten, Endverbraucher)
• Industriegetrieben
• Gemeinsame Definition und Erstellung einer
  strategischen Forschungsagenda (mittel- bis
  langfristig)
• Input zur Entwicklung der thematischen
  Programme im 7. RP
• Einige wenige werden als Gemeinsame
  Technologieinitiativen (Joint Technology
  Initiatives) etabliert
• Neuer Weg zur Realisierung von public-private
  partnerships auf EU-Ebene mit definierter
  rechtlicher Struktur

9
Inhalt

• Generelle Gesichtspunkte des 7.
  EU-Rahmenprogramms
• Ausschreibungsthemen zu Health und
  Biotechnologies, Agriculture, Food and
  Fisheries
• Das Programm IDEAS
• Nächste Schritte

10

• Ziele
• Verbesserung der Gesundheit der europäischen
  Bevölkerung
• Stärkung der europ. Industrie/Firmen im Bereich
  Gesundheit
• Blick auf globale Gesundheitsfragen
• (z.B. Epidemien
• Schwerpunkte
• Translationale Forschung (Grundlagenforschung ?
  klinische
  Anwendung)
• Neue Therapien (Entwicklung und Validierung)
• Methoden zur Gesundheitsförderung,
  Krankheitsprävention
• Diagnostische Instrumente und medizinische
  Technologien
• Effiziente Gesundheitssysteme

Thema 1- Gesundheit (6.050 Mio. Euro)
11
Theme 1 HEALTH (6.000 Mio. )
Activities
12

• High-throughput research
• Unifying human and model organism genetic
  variation databases
• Temporal and spatial proteomics to study
  biological processes relevant to human health
• Groundbreaking techniques for DNA sequencing and
  genotyping
• 2. Call
• SME-driven collaborative research projects for
  developing tools and technologies for
  high-throughput research
• Detection, Diagnosis and Monitoring
• Development of a hybrid imaging system
• Novel optical methodologies for detection,
  diagnosis and monitoring of disease or
  disease-related processes
• Novel targeted imaging probes for early in vivo
  diagnosis and/or evaluation of response to
  therapy
• In vivo image-guidance for cell therapy
• 2. Call
• Standardisation and improvement of pre-analytical
  procedures for in vitro diagnostics
• High throughput molecular diagnostics in
  individual patients for genetic diseases with
  heterogeneous clinical presentation

13

• Predicting suitability, safety and efficacy of
  therapies
• Thema zum Großteil durch Innovative Medicines
  Initiative (IMI) abgedeckt!
• Novel alternative testing strategies for use in
  pharmaceutical discovery and development
• Bottlenecks in reduction, refinement and
  replacement of animal testing in pharmaceutical
  discovery and development
• Promotion, development, validation, acceptance
  and implementation of QSARs (quantitative
  structure-activity relationship) for toxicology
• Alternative testing strategies for the assessment
  of the toxicological profile of nanoparticles
  used in medical diagnostics
• In silico modelling for ADMET outcomes

14

• Innovative therapeutic approaches and
  interventions
• Development and production of new generation
  antibodies
• Innovative approaches for the development of
  vaccines for young children
• Immunotherapy of human food allergies
• 2.Call
• Development of emerging gene therapy tools and
  technologies for clinical application
• Stem cell lines for cell-based therapies.
• Development of stem cell culture conditions.
• Stem cells for kidney regeneration.
• Adding value to EU stem cell therapy research
  scientific communication and future perspectives.

15

• Large-scale data gathering
• Networking biobanking initiatives across Europe
  developing standards and norms for existing and
  future human sample biobanks
• Molecular epidemiological studies in existing
  well characterised European (and/or other)
  population cohorts
• Comparative studies of genetic variation in
  humans towards a reference population in Europe
• Characterisation and variability of the microbial
  communities in the Human Body
• Structure-function analysis of membrane-transporte
  rs and channels for the identification of
  potential drug target sites
• High throughput analysis of lipids and
  lipid-protein interactions
• Genome-wide association studies in mammalian
  non-rodent models for the identification of genes
  relevant to human health and disease

16

• Systems biology
• A system approach to eukaryotic unicellular
  organism biology
• Modelling of T-cell activation
• Fundamental approaches to stem cell
  differentiation
• Developing an integrated in vitro, in vivo and
  systems biology modelling approach to
  understanding apoptosis in the context of health
  and disease
• 2. call
• Multidisciplinary fundamental genomics and
  molecular biology approaches to study basic
  biological processes relevant to health and
  diseases
• Coordination and Support Actions in large-scale
  data gathering and systems biology
• Traditional Chinese Medicine in post-genomic era.
  Specific International Cooperation Action.
  Targeted region China.

17

• Brain and related diseases
• Stroke and mechanisms underlying ischemic brain
  damage
• Coding in neuronal assemblies
• Neurobiology of anxiety disorders
• Memory loss underlying mechanisms and therapy
• From basic spinal mechanisms to spinal cord
  disease and trauma.
• Neuron-glia interactions in health and disease
• 2. Call
• Restorative approaches for therapy of
  neurodegenerative diseases.
• From mood disorders to experimental models.
• Neuronal mechanisms of vision and related
  diseases.
• Childhood and adolescent mental disorders.
  Specific International Cooperation Action. Target
  regions Eastern Europe and Central Asia and
  Western Balkans.

18

• Human Development and Ageing
• Novel approaches to reconstitute normal immune
  function at old age.
• Termination of developmental processes and their
  reactivation in adult life
• Biomarkers of ageing.
• Increasing the participation of elderly in
  clinical trials.
• Research on human development and/or healthy
  ageing across the EU

19

• Anti-microbial drug resistance including fungal
  pathogens
• 2. Call
• Novel targets for drugs against Gram negative
  bacteria.
• Host-pathogen interactions in infections by
  Streptococcus pneumoniae.
• An integrated platform for development and
  clinical evaluation of point-of-care diagnostic
  devices for microbial detection, antibiotic
  susceptibility determination and biomarkers
• Molecular epidemiology to control nosocomial and
  community spreading of highly virulent multi-drug
  resistant strains of bacterial pathogens.
• Health and economic cost of antimicrobial
  resistance.
• Conference on genetic and biochemical tools for
  postgenomic physiological analysis of
  Staphylococcus, in particular MRSA.

20

• HIV, AIDS, malaria and tuberculosis
• HIV/AIDS Drug Discovery and Preclinical
  Development
• Highly innovative approaches for research into
  host-pathogen interaction in tuberculosis
• Development of fast tests for the diagnosis of
  Multi-Drug-Resistant strains of HIV, malaria and
  tuberculosis and of latent tuberculosis infection
  (LTBI).
• Addressing knowledge gaps in pregnancy malaria.
• New HIV Vaccines inducing broadly-reactive
  neutralising antibodies.
• 2. Call
• Network on HIV and anti-HIV drug resistance
• HIV and Hepatitis co-infection
• Blocking the transmission of malaria the
  mosquito vector target.
• European network for study and clinical
  management of TB drug resistance.
• Support platform for the development of PRD
  vaccines
• Highly innovative research in HIV/AIDS, malaria
  and tuberculosis between Indian and European
  partners. (SICA, Targeted Region India)
• Coordination of European research activities with
  global initiatives, including Public-Private-Partn
  erships (SICA Targeted Regions ICPC).
• Next generation of researchers for HIV/AIDS,
  malaria, tuberculosis and neglected infectious
  diseases (SICA Targeted Regions ICPC).

21

• Potentially new and re-emerging epidemics
• Development of broadly protective influenza
  vaccine candidates.
• Identifying immunological mechanisms of
  protection for influenza vaccines
• Standardisation of immunological assays including
  surrogate markers for evaluation of new influenza
  vaccines in clinical trials
• Innovative point-of-care diagnostic tests for
  influenza.
• Development of additional treatment strategies
  for patients suffering from highly pathogenic
  influenza.
• Development of pandemic influenza containment and
  mitigation strategies.
• Supporting highly innovative inter-disciplinary
  research on influenza.
• Influenza research in collaboration with Asian
  partners. (SICA, Targeted regions Asia)
• 2. Call
• Strengthening research on prediction,
  identification, modelling and surveillance of
  newly emerging infectious diseases in humans.
• Definition of research needs and priorities in
  Europe in the area of Emerging Infectious
  Epidemics.

22

• Cancer
• Translating the knowledge on non-coding RNAs
  linked to the aetiology of cancer into novel
  diagnosis and therapy strategies.
• Translating clinical omics-technology
  (genomics, proteomics, metabolomics) into
  innovative cancer biomarkers aiding in early
  diagnosis, prognosis and treatment selection of
  cancer patients.
• Genomic instability and genomic alterations in
  pre-cancerous lesions and/or cancer.
• Novel cancer screening methods.
• Optimising research on end of life care of cancer
  patients.
• Understanding and fighting metastasis.
• Improving targeted drug delivery to cancer cells
  for cancer therapeutics other than gene therapy
• Developing high-throughput bioassays and models
  for human cancers in lower species.
• 2. Call
• Innovative combination clinical trials for
  multimodal cancer therapy.
• Role of inflammation in tumour initiation and
  progression.
• Epidemiology of gene-environment interactions
  involved in carcinogenesis.
• Translating the hypoxic tumour microenvironment.
• ERA-NET on optimisation of the use of cancer
  registries for cancer research purposes
• Studying cancer aetiology in Latin America. (SICA)

23

• Cardiovascular Disease
• Molecular basis of the inflammatory response and
  associated vascular remodelling in
  arteriosclerosis.
• Vascular remodelling in aneurysmal disease.
• Combating stroke.
• 2. Call
• Congenital pathologies affecting the heart.
• Cell therapies for the treatment of heart
  ischemia.
• Organ imaging in CVD.
• Integrating pharmacogenomic approaches into the
  treatment of CVD.

24

• Diabetes and Obesity
• Early processes in the pathogenesis of type 1
  diabetes and strategies for early prevention.
• Combined forms of diabetes in children.
• Insulin resistance as a key factor in the
  development of diabetes and metabolic syndrome.
• Pathophysiological mechanisms related to excess
  fat.
• A road-map for diabetes research.
• 2. Call
• Nutritional signals and the development of new
  diabetes/obesity therapeutic agents.
• Markers and treatment for diabetic neuropathy
  complications.
• Geno- and phenotypical differentiation of type 2
  subjects and monogenic subjects.
• Use of beta cell imaging in diabetes mellitus.

25

• Rare Diseases
• Natural course and pathophysiology of rare
  diseases.
• Research capacity-building in the field of rare
  diseases.
• Other Chronic Diseases
• Osteoarthritis.
• Inflammatory bowel disease.
• Osteoporosis signalling pathways in bone
  formation and homeostasis.
• Genetic factors of Osteoporosis.
• Intervertebral disc degeneration prevention and
  repair.
• Innovative concepts in chronic obstructive
  pulmonary disease pathogenesis (COPD).
• Hearing impairment and degeneration.
• Impairment of touch and proprioception at old
  age.
• Visual impairment and degeneration.
• 2. Call
• Understanding and combating age-related muscle
  weakness.
• Translational research aiming for a treatment of
  urinary incontinence.

26

• Translating clinical research into clinical
  practice including better use of
• medicines, and appropriate use of behavioural and
  organisational
• interventions and health therapies and
  technologies
• 2.call
• Implementation of research into healthcare
  practice
• Self-medication and patient safety
• Patient Safety Research Network
• Improving clinical decision making
• Better use of medicines.
• Continuity of clinical care.
• Patient self-management of chronic disease.
• Quality, solidarity and sustainability of health
  systems

27

• Enhanced health promotion and disease prevention
  
• 2.call
• Promoting healthy behaviour in children and
  adolescents
• Interventions addressing the gradient of health
  inequalities
• Public health interventions addressing the abuse
  of alcohol.
• Evaluation of suicide prevention strategies
  across and within European countries.
• Improve vaccination coverage
• Horizontal Coordination and Support Actions
  across Optimising the Delivery
• of Health Care to European Citizens
• 2.call
• Disease networks of centres of reference.

28

• Specific International Cooperation Actions for
  Health System Research
• 2.call
• Epidemiological investigations into long-term
  trends of population health as consequence of
  socio-economic transitions, including life-style
  induced health problems. SICA (Mediterranean
  Partner countries, Russia, Eastern European and
  Central Asia)
• Universal and equitable access to health care and
  health financing. SICA (MCP, ACP, Asia and Latin
  America)
• Health care intervention research optimising
  hospital care. SICA (Western Balkans.)
• Health care intervention research improving
  pre-natal and maternal care. SICA (ACP and
  Mediterranean Partner Countries)

29

• Coordination and Support Actions across the Theme
• Reinforcing the network of National Contact
  Points (NCP) for the Seventh Framework Programme
  under Health Theme by promoting transnational
  co-operation.)
• Promoting participation of high-technology
  research intensive SMEs, operating in the
  biomedical engineering and other medical
  technology sectorsrelevant to Health Theme.
• Assessment and valorisation of project outcome
  for hightechnology and research intensive SME
  participating to Framework Programmes of Research
  in the healthcare sector.
• Science communication actions.
• Initiatives to foster dialogue and debate on
  health research issues of interest to the public.
• Studies on the impact of EU legislation on health
  research and related developments and
  applications.
• 2.call
• Promotion and facilitation of international
  cooperation in areas relevant to the objectives
  of this theme. (SICA, ICPC)
• Responding to EU policy needs (2.call)
• Paediatric medicinal products, Drug safety
  research, Living and work conditions, Health
  statistics, Tobacco Control

30
Example Innovative Medicines - en route to a
Joint Technology Initiative

• Accelerated Development of safe and more
  effective medicines
• Revitalization of the the biopharmaceutical
  research and development (RD) environment for
  Europe to become more competitive
• Improving the collaboration between all relevant
  actors from public and private organisations
  (public-private partnerships)
• Draft and Implementation of a European Research
  Agenda
• Second version of the Strategic Research
  Agenda published recently
• First Calls expected for end of 2007/beginning
  of 2008
• http//europa.eu.int/comm/research/fp6/index_en.cf
  m?p1_innomed
• http//rp7.ffg.at/RP7.aspx_param_target_is_116120.
  v.aspx

31

•  Innovative Medicines 
• 2. version of the  Strategic Research Agenda 
• 4 main topics
• Safety
• Early safety evaluation and risk assessment,
  creation of a European Centre for Drug Safety
• Efficacy
• Predictive pharmacology, biomarker identification
  and validation, patient recruitment and risk
  assessment
• Knowledge Management
• New technologies to control and analyse enormous
  quantities of information in an integrative and
  predictive way
• Education and Training
• Bridge gaps in expertise required to strengthen
  the biopharmaceutical RD process, creation of a
  European Medicines Research Academy

32

• Technologieplattform
•  Innovative Medicines 
• Contact in Austria
• Univ. Prof. Dr. Hans Georg Eichler,
• Vice Rector of the Medical University in
  Vienna
• vr_forschung_at_meduniwien.ac.at

33

• Thema 2 - Lebensmittel, Landwirtschaft,
• Fischerei und Biotechnologie
• (1.935 Mio Euro)
• Ziel
• Aufbau einer wissensgestützten Bio-Wirtschaft
• Schwerpunkte
• Sicherere, gesündere und hochwertigere
  Lebensmittel
• Tierschutz
• Nachhaltige Produktion und Verwendung
  nachwachsender Bio-Rohstoffe
• Epizoonosen und Zoonosen
• Lebensmittelbedingte Dysfunktionen
• Nachhaltigkeit und Sicherheit der
  landwirtschaftlichen Erzeugung und der Fischerei

34
Thema 2 - Lebensmittel, Landwirtschaft,
Fischerei und Biotechnologie
35

• Development of new tools and processes to support
  RD in crop plants molecular breeding
• Mining genomics information of farm animals to
  generate new information on the genetic basis of
  phenotypes important to sustainable animal
  production
• Development of genetic systems for crop
  improvement through a systems biology approach
• Development of technologies and tools for the
  exploitation of livestock genome
• Using new technologies to identify (re-)emerging
  pathogens from wildlife reservoirs
• Annual food crops with improved tolerance to
  multiple abiotic stresses
• Genomics for cereal improvement for food, feed
  and non-food uses
• Development of more efficient risk analysis
  techniques for pests and pathogens of
  phytosanitary concern
• Reducing the need for external inputs in
  high-value protected horticultural and ornamental
  crops
• Developing new methods for valuing and marketing
  of currently non-marketable forest goods and
  services
• Coordination of Agricultural Research in the
  Mediterranean
• Reduction of N excretion in ruminants
• From capture based to self-sustained aquaculture
• Breeding tools for improved livestock products
• The farm of tomorrow
• GMO cost-effective and crop-specific co-existence
  measures
• (...)

36

• Smart control for improved food and feed
  technologies (Large collaborative project)
• Assessment and improvement of existing food and
  feed technologies (Small collaborative project)
• Nano-devices for quality assurance, food safety
  and product properties(Small collaborative
  projects)
• Exposure to food additives, flavourings, and
  migrants coming from food contact materials
  dietary intake models (Large collaborative
  project)
• Innovative and safe packaging (Small
  collaborative project)
• Post Market Monitoring of the effect of GM food
  and feed on human and animal health (Small
  collaborative project)
• Converging technologies and their potential for
  the food area (Small collaborative project)
• Detecting contaminants in the Food and Feed Chain
• ()

37

• ENGERGY PLANTS Novel plants for energy
  production (Small collaborative project)
• GREEN OIL Plants providing oils for the future
  (Large collaborative project)
• BIO-VET-Pharming Plant made recombinant
  pharmaceuticals for animals (Network of
  Excellence)
• FOREST PRODUCTS New forest based products and
  processes (Large collaborative project)
• GREEN FACTORY The expression and accumulation
  of valuable industrial compounds in plants (Large
  collaborative project)
• Improved Microbes Metabolic engineering and
  modelling (Coordination and Support Action)
• IMPROVED MICROBES for the Environment Microbial
  gene expression under conditions of stress (Large
  collaborative project)
• ANIMAL BY PRODUCTS - Nove methods of treatment
  of animal by products for the production of
  substances with biologically valuable functional
  properties (Small collaborative project)
• And many more.

38
EuropäischeTechnologie-Plattformen im Bereich
Lebensmittel, Landwirtschaftund Biotechnologie

• Plants for the Future
• http//www.epsoweb.org/Catalog/TP/index.htm
• Food for Life
• http//etp.ciaa.be/asp/home/welcome.asp
• Global Animal Health
• http//www.ifahsec.org/Europe/EUPlatform/Platform.
  htm
• Farm Animal Breeding and Reproduction
• http//www.fabretp.org/

39
Weitere relevante Themen der 1.Ausschreibung aus
anderen Bereichen

• Information and Communication Technologies
• Objective ICT-2007.5.3 Virtual Physiological
  Human
• Nanosciences, Nanotechnologies, Materials and new
  Production
• Technologies
• Creation of a critical and commented database on
  the health,
• safety and environmental impact of nanoparticles
• Process intensification in chemicals production
• Substantial innovation in the European medical
  industry development of
• nanotechnology-based systems for in-vivo
  diagnosis and therapy (in
• Coordination with topic HEALTH-2007-2.4.1-7 and
  HEALTH-2007-1.2-3 in
• Theme 1 "Health")

40
Inhalt

• Generelle Gesichtspunkte des 7.
  EU-Rahmenprogramms
• Health und Food, Agriculture and Fisheries, and
  Biotechnology in der 1. Ausschreibung
• Das Programm IDEAS

41
Das Programm IDEAS ein Überblick

• Ziele des Spezifischen Programms IDEAS
• Rolle des European Research Council (ERC)
• Förderlinien

42
Worum geht es beim Spezifischen Programm IDEAS?

• Grundlagenorientierte Spitzenforschung
  (Pionierforschung)
• Alle Forschungsbereiche
• Umsetzung durch European Research Council
  ERC

43

• Forschung an den Grenzen des Wissens
  (Pionierforschung)
• riskant
• interdisziplinär
• schwer voraussagbar in ihrer praktischen
  Anwendung
• Vermeidung unzeitgemäßer Unterscheidungen
• Grundlagenforschung - angewandte Forschung
• Wissenschaft -Technologie
• traditionelle Disziplinen

44
Wozu Pionierforschung?
45
Welche Rolle spielt der ERC?
Mittel des spezifischen Programms IDEAS werden
für die Aktivitäten des European Research Council
(ERC) eingesetzt

• Hebelwirkung -gt strukturelle Verbesserung im
  Europäischen Forschungssystem
• Erhöhung der Exzellenz, Dynamik und Kreativität
  im Bereich Grundlagenforschung
• Stärkung vorhandener Potentiale an den Grenzen
  des Wissens
• Einziges Evaluierungskriterium EXZELLENZ

46
ERC Struktur und Organisation

• Forschungsrat (Scientific Council)
• Unabhängige Festlegung der ERC-Strategie,
  wissenschaftlicher Zielsetzungen, Abwicklung
• Unterstützt durch Agentur (Dedicated
  Implementation Structure)
• Agentur (Dedicated Implementation Structure)
• Praktische Implementierung und operatives
  Management
• Europäische Kommission
• stellt die finanziellen Mittel zur Verfügung
• sorgt für Autonomie des ERC

47
ERC - Wissenschaftliche Schwerpunkte

• Physikalische und technische Wissenschaften
• Lebenswissenschaften
• Sozial- und Geisteswissenschaften

48
ERC Panels

• 20 Scientific Panels
• 20 Panel-Vorsitzende(International anerkannte
  WissenschafterInnen und ForscherInnen)
• 200 Panel-Mitglieder(WissenschafterInnen und
  ForscherInnen aus den jeweiligen Fachgebieten)
• 1000 - 2000 GutacherInnen
• (Consultation letter an Europäische
  Forschungsorganisationen)

49
Welche Förderschienen gibt es?

• ERC Starting Independent Researchers Grants(ERC
  Starting Grant)
• ERC Advanced Investigator Grants(ERC Advanced
  Grant)

50

• ERC Starting Grants
• Unterstützt werden exzellente Forschende aller
  Nationalitäten, die ihr erstes selbständiges
  ForscherInnen-Team in Europa etablieren wollen.
  Der Weg in die Unabhängigkeit wird unterstützt
• Ausschreibung 22. Dezember 2006
• Einreichfrist April 2007 für die erste Stufe
• ERC Advanced Grants
• Für exzellente ForscherInnen und
  WissenschafterInnen, die bereits eine gewisse
  Unabhängigkeit erlangt haben -gt als Folgeprogramm
  des Starting Grants zu verstehen
• Ausschreibung Sommer 2007
• Einreichfrist Anfang 2008

51
ERC Starting Grants

• Projektvorschläge werden von einzelnem/r
  Forscher/in (Principal investigator)
  eingereicht.
• Durchführung der Projekte transnationale oder
  nationale Teams
• Teamleiter jede Nationalität
• befindet sich in einer
  Forschungseinrichtung in
  Europa (EU25, Kandidatenländer, assoziierte
  Länder)
• Teammitglieder jede Nationalität
• Verträge werden zwischen dem ERC und der
  Gasteinrichtung des Teamleiters abgeschlossen,
  die für das unabhängige Arbeiten des Teams
  garantieren muß.

52
ERC Starting Grants - wer reicht ein?

• TeamleiterIn (Principal Investigator)
• Über 2, weniger als 8 Jahre Forschungserfahrung
  nach Abschluß des Doktorats.
• Teamleiter darf nur in einem Starting Grant
  Projekt tätig sein.
• Keine Beschränkungen bei der Wahl der
  Projektinhalte.
• Es muß das erste unabhängige Team sein.
• Fähigkeit, eigenes Team zu etablieren.

53
ERC Starting Grants - Evaluierungskriterien

• Principal Investigator Potential to become a
  world class research leader
• Quality of research output
• Intellectual capacity and creativity
• Quality of the proposed research project
• Ground-breaking nature of the research
• Potential impact
• Methodology
• Research Environment
• Transition to independence
• Host institution (normally applicant legal
  entity)
• Participation of other legal entities

54
ERC weitere Information

• Kontakt
• Ralf König
• ralf.koenig_at_ffg.at
• 43 (0)57755 - 4601
• http//rp7.ffg.at/erc
• http//rp7.ffg.at/erc
• http//erc.europa.eu
• http//cordis.europa.eu/fp7/ideas.htm
• http//ec.europa.eu/research/future/index_en.cfm

55
Vielen Dank für Ihre Aufmerksamkeit viel
Erfolg für Ihre Projekte im 7. Rahmenprogramm!